Agile Therapeutics

Agile Therapeutics, Inc. (NASDAQ: AGRX), the commercial-stage women’s healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel and ethinyl estradiol) transdermal system, its birth control patch. The company...

Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research. The firm’s focus and area of expertise is in small and micro-cap companies, some of which are...

On August 9, Agile Therapeutics (NASDAQ: AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla®(levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and...

Agile Therapeutics, Inc.’s (NASDAQ: AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women’s healthcare company toward its $25-$30 million net annual revenue target for 2023. The companies teamed up last year to make Twirla® (levonorgestrel and...

This month, Agile Therapeutics, Inc. (NASDAQ: AGRX) announced partnerships with FPA Women’s Health and vitaCare Prescription Services that will expand access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, its low-dose weekly birth control patch. The news builds on...

In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services. It directs the Secretaries of Health and Human Services (HHS), Labor and the Treasury to issue new guidance that ensures all contraceptives approved by...

H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ: AGRX) this month, setting a price target of $12 per share. The $12 price target is based on the 1:50 reverse split and the $7.5 million raised in Agile’s public offering in May. Despite challenges faced...

Agile Therapeutics (NASDAQ: AGRX) announced the closing of its public offering in May. The women’s healthcare company raised $7.5 million in gross proceeds after selling over 1.8 million shares of common stock at $3.95 per share. The offering came just weeks after Agile released its first...

Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently interviewed by Benzinga.  Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Its product and product candidates are designed to provide...

Women are itching for more birth control options that cater to their unique needs and preferences. While traditional forms of birth control – such as the pill and condoms – have been reliable options for many years, they don’t satisfy everyone. For example, a recent study showed...

The invention of birth control in the 1960s revolutionized women's health and their lives. In 2022, the contraceptive market was valued at $8.3 billion and it is projected to grow at a compound annual growth rate (CAGR) of around 5.16% from 2023 to 2030. With the overturning of Roe v Wade,...

Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently a guest on Benzinga’s All Access. Agile Therapeutics is a women’s healthcare company “dedicated to fulfilling the unmet needs of today’s women.” The company looks to develop novel...

Al Altomari, Chairman and CEO of Agile Therapeutics Inc (NASDAQ: AGRX), was recently interviewed by Benzinga. Agile Therapeutics says it is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Its products and product candidates are designed to provide...

Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023.  The Princeton, New Jersey-based company’s Twirla patch gives women the choice to not take a birth control pill every...

Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options. The company’s product and product candidates are designed to provide women with contraceptive options that offer freedom from...